Advanced Steatosis Grade, Diabetes Independently Raise HCC Risk After Hepatitis C Cure, Study Finds
Steatosis severity and individual cardiometabolic risk factors shape hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease, according to a longitudinal study published in Gut.
Researchers in China evaluated 700 patients who received hepatocellular carcinoma surveillance twice per year after achieving a hepatitis C cure, DocWireNews reported. The study team used vibration-controlled transient elastography to measure steatosis grade and analyzed cardiometabolic risk factors following viral clearance.
Cumulative hepatocellular carcinoma prevalence differed significantly across steatosis grades, while no difference was observed across cardiometabolic burden, according to findings published in Gut. Advanced steatosis grade independently correlated with hepatocellular carcinoma risk with an adjusted hazard ratio of 2.15 for S3 versus S1.
Pre-diabetes or type 2 diabetes significantly correlated with hepatocellular carcinoma risk with an adjusted hazard ratio of 2.33, the study authors stated. The researchers concluded that advanced steatosis grade and glycemic irregularities independently associate with increased hepatocellular carcinoma risk after hepatitis C cure.
| Risk Factor Comparison | Adjusted Hazard Ratio | 95% Confidence Interval | P-Value |
|---|---|---|---|
| Steatosis Grade (S3 vs S1) | 2.15 | 1.25 to 3.69 | 0.005 |
| Cardiometabolic Risk Factors | 2.33 | 1.38 to 3.94 | 0.002 |
Steatosis was graded by vibration-controlled transient elastography using controlled attenuation parameter cut-offs of 248 to 267, 268 to 279, and 280 decibels per meter or higher, corresponding to S1, S2, and S3 respectively, per data reported in Gut. The multivariable analyses were adjusted for various factors including sex, liver stiffness, alpha-fetoprotein, and age, DocWireNews reported.
The specific impacts of steatosis grade and cardiometabolic burden among patients with metabolic dysfunction-associated steatotic liver disease remain unclear, according to research published in Gut. Whether ongoing surveillance protocols should be dynamically adjusted based on these elastography cut-offs is not yet known.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.